
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9119771/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinaemia in patients with uraemia. Lancet, The, 2003, 361, 1693-1699.	13.7	395
2	Occurrence of Dâ€aspartic acid and Nâ€methylâ€Dâ€aspartic acid in rat neuroendocrine tissues and their role in the modulation of luteinizing hormone and growth hormone release. FASEB Journal, 2000, 14, 699-714.	0.5	212
3	Mechanism of erythrocyte accumulation of methylation inhibitor S-adenosylhomocysteine in uremia. Kidney International, 1995, 47, 247-253.	5.2	109
4	Possible mechanisms of homocysteine toxicity. Kidney International, 2003, 63, S137-S140.	5.2	93
5	Increased methyl esterification of altered aspartyl residues in erythrocyte membrane proteins in response to oxidative stress. FEBS Journal, 2000, 267, 4397-4405.	0.2	82
6	Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes. Nephrology Dialysis Transplantation, 2009, 24, 3756-3763.	0.7	78
7	Membrane protein damage and methylation reactions in chronic renal failure. Kidney International, 1996, 50, 358-366.	5.2	62
8	Epigenetics in hyperhomocysteinemic states. A special focus on uremia. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 892-899.	2.4	56
9	Low hydrogen sulphide and chronic kidney disease: a dangerous liaison. Nephrology Dialysis Transplantation, 2012, 27, 486-493.	0.7	47
10	Reduction of the genomic damage level in haemodialysis patients by folic acid and vitamin B12 supplementation. Nephrology Dialysis Transplantation, 2008, 23, 3272-3279.	0.7	45
11	Gut-Derived Metabolites and Their Role in Immune Dysfunction in Chronic Kidney Disease. Toxins, 2020, 12, 245.	3.4	44
12	Homocysteine metabolism in renal failure. Current Opinion in Clinical Nutrition and Metabolic Care, 2004, 7, 53-57.	2.5	42
13	Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to the calcimimetics era. BMC Surgery, 2013, 13, S4.	1.3	41
14	PROGRESS IN UREMIC TOXIN RESEARCH: Hyperhomocysteinemia in Uremia—A Red Flag in a Disrupted Circuit. Seminars in Dialysis, 2009, 22, 351-356.	1.3	39
15	Hydrogen sulfide reduces cell adhesion and relevant inflammatory triggering by preventing ADAM17â€dependent TNFâ€Î± activation. Journal of Cellular Biochemistry, 2013, 114, 1536-1548.	2.6	38
16	Plasma Protein Aspartyl Damage Is Increased in Hemodialysis Patients: Studies on Causes and Consequences. Journal of the American Society of Nephrology: JASN, 2004, 15, 2747-2754.	6.1	37
17	Divergent behavior of hydrogen sulfide pools and of the sulfur metabolite lanthionine, a novel uremic toxin, in dialysis patients. Biochimie, 2016, 126, 97-107.	2.6	37
18	Homocysteinylated Albumin Promotes Increased Monocyte-Endothelial Cell Adhesion and Up-Regulation of MCP1, Hsp60 and ADAM17. PLoS ONE, 2012, 7, e31388.	2.5	31

#	Article	IF	CITATIONS
19	Impact of the Uremic Milieu on the Osteogenic Potential of Mesenchymal Stem Cells. PLoS ONE, 2015, 10, e0116468.	2.5	31
20	Renal phenotype in Bardet-Biedl syndrome: a combined defect of urinary concentration and dilution is associated with defective urinary AQP2 and UMOD excretion. American Journal of Physiology - Renal Physiology, 2016, 311, F686-F694.	2.7	27
21	Plasma proteins containing damaged L-isoaspartyl residues are increased in uremia: Implications for mechanism. Kidney International, 2001, 59, 2299-2308.	5.2	26
22	In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis. Kidney International, 2005, 68, 1223-1229.	5.2	26
23	Gases as Uremic Toxins: Is There Something in the Air?. Seminars in Nephrology, 2014, 34, 135-150.	1.6	24
24	Exploring Key Challenges of Understanding the Pathogenesis of Kidney Disease in Bardet–Biedl Syndrome. Kidney International Reports, 2020, 5, 1403-1415.	0.8	23
25	Cytoskeletal behaviour in spectrin and in band 3 deficient spherocytic red cells: evidence for a differentiated splenic conditioning role. British Journal of Haematology, 1996, 93, 38-41.	2.5	22
26	The Sulfur Metabolite Lanthionine: Evidence for a Role as a Novel Uremic Toxin. Toxins, 2017, 9, 26.	3.4	22
27	The role of the intestinal microbiota in uremic solute accumulation: a focus on sulfur compounds. Journal of Nephrology, 2019, 32, 733-740.	2.0	22
28	Metabolic consequences of hyperhomocysteinemia in uremia. American Journal of Kidney Diseases, 2001, 38, S85-S90.	1.9	20
29	Hyperhomocysteinemia and macromolecule modifications in uremic patients. Clinical Chemistry and Laboratory Medicine, 2005, 43, 1032-8.	2.3	18
30	The MicroRNA 15a/16–1 Cluster Down-regulates Protein Repair Isoaspartyl Methyltransferase in Hepatoma Cells. Journal of Biological Chemistry, 2011, 286, 43690-43700.	3.4	17
31	ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease–Mineral and Bone Disorder. , 2017, 27, 453-457.		17
32	Homocysteine and chronic kidney disease: an ongoing narrative. Journal of Nephrology, 2019, 32, 673-675.	2.0	17
33	Hyperhomocysteinemia in Chronic Renal Failure: Alternative Therapeutic Strategies. , 2012, 22, 191-194.		16
34	Proteomics and metabolomics studies exploring the pathophysiology of renal dysfunction in autosomal dominant polycystic kidney disease and other ciliopathies. Nephrology Dialysis Transplantation, 2020, 35, 1853-1861.	0.7	16
35	DNA Methylation Dysfunction in Chronic Kidney Disease. Genes, 2020, 11, 811.	2.4	16
36	Increased Membrane-Protein Methylation in Hereditary Spherocytosis. A Marker of Cytoskeletal Disarray. FEBS Journal, 1995, 228, 894-898.	0.2	16

#	Article	IF	CITATIONS
37	Hydrogen Sulfide, the Third Gaseous Signaling Molecule With Cardiovascular Properties, Is Decreased in Hemodialysis Patients. , 2010, 20, S11-S14.		15
38	Hydrogen Sulfide, a Toxic Gas with Cardiovascular Properties in Uremia: How Harmful Is It?. Blood Purification, 2011, 31, 102-106.	1.8	15
39	Therapy of Hyperhomocysteinemia in Hemodialysis Patients: Effects of Folates and N-Acetylcysteine. , 2012, 22, 507-514.e1.		14
40	Uremic Toxin Lanthionine Interferes with the Transsulfuration Pathway, Angiogenetic Signaling and Increases Intracellular Calcium. International Journal of Molecular Sciences, 2019, 20, 2269.	4.1	14
41	Secondary Hyperparathyroidism and Hypertension: An Intriguing Couple. Journal of Clinical Medicine, 2020, 9, 629.	2.4	14
42	Atherosclerosis determinants in renal disease: how much is homocysteine involved?. Nephrology Dialysis Transplantation, 2016, 31, 860-863.	0.7	13
43	Hyperhomocysteinemia and cardiovascular disease in uremia: The newest evidence in epidemiology and mechanisms of action. Seminars in Nephrology, 2004, 24, 426-430.	1.6	12
44	Altered folate receptor 2 expression in uraemic patients on haemodialysis: implications for folate resistance. Nephrology Dialysis Transplantation, 2013, 28, 1214-1224.	0.7	11
45	Zebrafish, a Novel Model System to Study Uremic Toxins: The Case for the Sulfur Amino Acid Lanthionine. International Journal of Molecular Sciences, 2018, 19, 1323.	4.1	11
46	Chitosan Gel to Treat Pressure Ulcers: A Clinical Pilot Study. Pharmaceutics, 2018, 10, 15.	4.5	10
47	Homocysteine in uremia. American Journal of Kidney Diseases, 2003, 41, S123-S126.	1.9	9
48	Plasma protein homocysteinylation in uremia. Clinical Chemistry and Laboratory Medicine, 2007, 45, 1678-82.	2.3	9
49	COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis. Kidney and Blood Pressure Research, 2020, 45, 357-362.	2.0	9
50	Enzymatic Detection of l-Isoaspartyl Residues in Food Proteins and the Protective Properties of Trehalose. Journal of Nutritional Biochemistry, 1997, 8, 535-540.	4.2	8
51	Toxic Effects of Hyperhomocysteinemia in Chronic Renal Failure and in Uremia: Cardiovascular and Metabolic Consequences. Seminars in Nephrology, 2006, 26, 20-23.	1.6	7
52	Urinary proteome in inherited nephrolithiasis. Urolithiasis, 2019, 47, 91-98.	2.0	7
53	Integrin Beta 1 Is Crucial for Urinary Concentrating Ability and Renal Medulla Architecture in Adult Mice. Frontiers in Physiology, 2018, 9, 1273.	2.8	6
54	Nephroplex: a kidney-focused NGS panel highlights the challenges of PKD1 sequencing and identifies a founder BBS4 mutation. Journal of Nephrology, 2021, 34, 1855-1874.	2.0	6

#	Article	lF	CITATIONS
55	Hydrogen sulfide increases after a single hemodialysis session. Kidney International, 2011, 80, 1108-1109.	5.2	5
56	Lanthionine and Other Relevant Sulfur Amino Acid Metabolites: Detection of Prospective Uremic Toxins in Serum by Multiple Reaction Monitoring Tandem Mass Spectrometry. Methods in Molecular Biology, 2019, 2007, 9-17.	0.9	5
57	L-Propionyl carnitine, homocysteine and S-adenosylhomocysteine in hemodialysis. Journal of Nephrology, 2007, 20, 63-5.	2.0	5
58	Hyperhomocysteinemia and protein damage in chronic renal failure and kidney transplant pediatric patientsItalian initiative on uremic hyperhomocysteinemia (IIUH). Journal of Nephrology, 2003, 16, 516-21.	2.0	4
59	The gasotransmitter hydrogen sulfide in hemodialysis patients. Journal of Nephrology, 2010, 23 Suppl 16, S92-6.	2.0	4
60	Is Homocysteine Toxic in Uremia?. , 2008, 18, 12-17.		3
61	Novel Applications of Lead Acetate and Flow Cytometry Methods for Detection of Sulfur-Containing Molecules. Methods and Protocols, 2019, 2, 13.	2.0	3
62	Uremic Toxin Lanthionine Induces Endothelial Cell Mineralization In Vitro. Biomedicines, 2022, 10, 444.	3.2	3
63	Hyperhomocysteinemia and the cardiovascular disease of uremia. Nutrition Research, 2004, 24, 839-849.	2.9	2
64	Legislative proposal in Italy to facilitate contacts between deceased organ donor families and transplant recipients. Journal of Nephrology, 2020, 33, 1333-1342.	2.0	2
65	Homocysteine Solution-Induced Response in Aerosol Jet Printed OECTs by Means of Gold and Platinum Gate Electrodes. International Journal of Molecular Sciences, 2021, 22, 11507.	4.1	2
66	MTHFR C677T polymorphism and skin color: The white man's blackness. Kidney International, 2004, 65, 2444.	5.2	1
67	Candidate Risk Factors for Cardiovascular Disease in CKD. Seminars in Nephrology, 2006, 26, 1-2.	1.6	1
68	Do elevated homocysteine levels predict mortality in chronic kidney disease stages 3–4?. Nature Clinical Practice Nephrology, 2006, 2, 614-615.	2.0	1
69	P0095MOLECULAR MECHANISMS OF THE CARDIOVASCULAR EFFECTS OF LANTHIONINE, A NEW UREMIC TOXIN, AND ITS INTERACTIONS WITH THE REDOX MICROENVIRONMENT. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
70	MO035COMPUTATIONAL MODELING APPROACH FOR THE COMPREHENSIVE INTERPRETATION OF RARE TUBULOPATHIES. Nephrology Dialysis Transplantation, 2021, 36, .	0.7	0